Targeted therapies in inflammatory bowel disease

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 465-469

  Siegmund, Britta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Genome wide association studies; Inflammatory bowel disease, pathogenesis; Targeted therapies

Indexed keywords

ANTIGEN; ANTIINFLAMMATORY AGENT; CLAUDIN 2; CLAUDIN 5; CLAUDIN 8; GAMMA INTERFERON; GLUTAMINE; INFLIXIMAB; INTERLEUKIN 13; MESALAZINE; PROBIOTIC AGENT; QUERCETIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ZINC;

APOPTOSIS; CROHN DISEASE; CYTOKINE RELEASE; ENTERITIS; ESCHERICHIA COLI; HUMAN; INTESTINE EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH ULCER; TH2 CELL; TIGHT JUNCTION; ULCERATIVE COLITIS; UPREGULATION;

HUMANS; INFLAMMATORY BOWEL DISEASES; TRANSLATIONAL RESEARCH;

EID: 70449485061     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233284     Document Type: Review

References (30)

1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
2. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476. (Pubitemid 41770166)
3. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157.
4. Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, et al: Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007; 56: 509-517.
5. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al: Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250. (Pubitemid 47080388)
6. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
7. Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, et al: Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor-- antibody treatment. Gut 2004; 53: 1295-1302.
8. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin-12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290.
9. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al: Anti-interleukin-
10. antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-2079.
11. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al: A genomewide association study identifies IL-23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
12. Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R, Keniry A, et al: IL- 23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007; 132: 1657-1664.
13. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
14. Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, et al: Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003; 112: 693-706.
15. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al: The orphan nuclear receptor ROR- t directs the differentiation program of proinflammatory IL-17+ T-helper cells. Cell 2006; 126: 1121-1133.
16. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, et al: Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25: 309-318.
17. Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, et al: IL-23 plays a key role in Helicobacter hepaticus -induced T-cell-dependent colitis. J Exp Med 2006; 203: 2485-2494.
18. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al: Interleukin-23 drives innate and T-cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-2483.
19. Neurath MF: IL-23: A master regulator in Crohn disease. Nat Med 2007; 13: 26-28.
20. Shigematsu T, Specian RD, Wolf RE, Grisham MB, Granger DN: MAdCAM mediates lymphocyte- endothelial cell adhesion in a murine model of chronic colitis. Am J Physiol 2001; 281:G1309-G1315.
21. Kato S, Hokari R, Matsuzaki K, Iwai A, Kawaguchi A, Nagao S, et al: Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J Pharmacol Exp Ther 2000; 295: 183-189.
22. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al: Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
23. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al: Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683. (Pubitemid 46695722)
24. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al: The effect of anti-- 4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472.
25. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon-- 1 a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
26. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381.
27. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368.
28. Berger JR, Koralnik IJ: Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 2005; 353: 414-416.
29. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean- Jacques J, Letvin NL, Koralnik IJ: A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127: 1970-1978.
30. Du Pasquier RA, Schmitz JE, Jean-Jacques J, Zheng Y, Gordon J, Khalili K, et al: Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004; 78: 10206-10210.